Response Biomedical Signs Agreement for Sale of $7.7M of Shares to OrbiMed

The funding is indicative of Response Biomedical's growth in China, and will "allow us to concentrate on accomplishing our operational goals as we move toward becoming cash flow positive," its CEO said.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories